Nine patients in the avelumab monotherapy arm crossed over to the avelumab plus cetuximab group and the median PFS after crossover was 11.3 months (5.8-NR). The median overall survival (OS) of the ...

Avelumab (Bavencio, EMD Serono INc), which is a programmed cell death ligand–1 (PD L1) inhibitor, has been approved for second-line use in patients with locally advanced or metastatic urothelial ...

Combination platinum-based chemotherapy is the standard first-line treatment for advanced urothelial carcinoma, but most patients have disease progression within 9 months; the median overall ...

The addition of maintenance avelumab to best supportive care extended OS for patients with previously untreated locally advanced or metastatic urothelial carcinoma, according to study results rele ...

A total of 886 patients were assigned to receive avelumab plus axitinib (442 patients) or sunitinib (444 patients). Among the 560 patients with PD-L1–positive tumors (63.2%), the median ...